BILLS-117hr254ih.pdf

2021 later than 1 year 10 years 2021 through 2024 as young as 3 years of age 90 annually 35 to 45 years JANUARY 11, 2021 1 years

SESSION H. R. 254 the ‘‘Neuromyelitis Optica

PO 00000 Frm 00010 PO 00000 Frm 00006 PO 00000 Frm 00007 PO 00000 Frm 00009 PO 00000 Frm 00003 Fmt PO 00000 Frm 00001 PO 00000 Frm 00004 PO 00000 Frm 00008 Fmt PO 00000 Frm 00002 PO 00000 Frm 00005 PO 00000 Frm 00011 Fmt

California the United States of America the United States

IH

Americans Afro-Caribbeans Latino Caucasians

DSK79L0C42PROD NMOSD Congress SEC NIH NMOSD Consortium APPROPRIATIONS National Neuromyelitis Optica Spectrum Disorder Consortium NMO Food and Drug Adminis- NATIONAL NEUROMYELITIS OPTICA SPECTRUM House of Representa- NEUROMYELITIS OPTICA SPECTRUM TIUM U.S.C. the Committee on Energy and Commerce the NMOSD Consortium Senate Minority Health and Health Disparities THE HOUSE OF REPRESENTATIVES Neuromyelitis Optica Spectrum Disorder the Public Health Service the Public Health Service Act

LEE Biospecimens

spectrum therapies disorder consortium diseases risk factors therapy patients factors causes unknown provide grants tar model effort